No registrations found.
ID
Source
Brief title
Health condition
ADHD
Sponsors and support
Intervention
Outcome measures
Primary outcome
-oscillatory power modulation during attentional performance
- DTI measures - FA and volume of major tracts associated with dopaminergic signaling (focus on Superior Liongitudinal Fasciculus)
- striatal brain volume
Secondary outcome
na
Background summary
Within the domain of spatial attention, it has been shown that changes in neuronal synchronization are fundamental to implement the mechanisms required for selective gating. Specifically, modulations in both the alpha (8-13Hz) and gamma band (30-90Hz) are predictive of performance in spatial attention tasks. Studies have reported that patients with Attention Deficit and Hyperactivity
Disorder (ADHD) show a reduced ability to modulate alpha band oscillations during covert attention, when compared to controls5. Stimulant medications (e.g. Methylphenidate) often provide effective treatment for ADHD symptoms, while little is known about the neuronal mechanisms by which they exert their effect. Given the role of neuronal oscillatory modulations in attentional performance, pharmacological intervention is expected to normalize the eventual differences in alpha and gamma band synchronization between ADHD patients and healthy subjects. Furthermore, investigation of anatomical differences between the two groups is performed to
identify the brain structures responsible for top-down attentional modulation.
Study objective
Within the domain of spatial attention, it has been shown that changes in neuronal synchronization are fundamental to implement the mechanisms required for selective gating. Specifically, modulations in the alpha (8-13Hz) and gamma band (30-90Hz) are predictive of performance in spatial attention tasks. Studies have reported that patients with Attention Deficit and Hyperactivity Disorder (ADHD) show a reduced ability to modulate alpha and gamma band oscillations during covert attention, when compared to controls. In addition, power modulation in the beta (15-30Hz) and Mu (9-11Hz) frequency bands, have also been shown to differ between controls and ADHD, hence indexing aberrant stimulus processing and motor activity. Stimulant medications (e.g. Methylphenidate) often provide effective treatment for ADHD symptoms, while little is known about the neuronal mechanisms by which they exert their effect. Given the role of neuronal oscillatory modulations in attentional performance, pharmacological intervention is expected to normalize the eventual differences in brain oscillations between ADHD patients and healthy subjects. Furthermore, investigation of anatomical differences between the two groups is performed to identify the brain structures responsible for top-down attentional modulation.
Study design
- variables measured during experiment
for ADHD, MEG and MRI data measured on and off (placebo) medication (1 week between two recordings)
Intervention
on/off medication (placebo / active medication(methykphenidate)) for the ADHD group.
no intervention for control group.
C Mazzetti
Kapittelweg 29
Nijmegen 6525EN
The Netherlands
+41 779383973
c.mazzetti@donders.ru.nl
C Mazzetti
Kapittelweg 29
Nijmegen 6525EN
The Netherlands
+41 779383973
c.mazzetti@donders.ru.nl
Inclusion criteria
controls
- 8-12 years old
- male
- no psychiatric dysorder
- IQ >80
ADHD
- diagnosis of ADHD (DSM IV)
- score in clinical range of ADHD rating scale
- Pharmacological treatment with Stimulant medication for the treatment of ADHD (either long- or shortacting
formulations), which started at least 3 months before the inclusion in the study.
Exclusion criteria
(1) Neurological disorders (e.g. epilepsy) currently or in the past.
(2) Cardiovascular disease currently or in the past.
(3) Serious motor or perceptual handicap.
(4) Standard MRI Exclusion criteria according to DCCN regulations.
The presence of comorbid symptoms will be documented: for the control group, by scores for problem
behaviours on the Childhood Behavior Checklist (CBCL) , completed by the parents; For the ADHD group
a psychiatrist from the Karakter Instituut will perform a clinical evaluation assessing eventual comorbities.
Design
Recruitment
IPD sharing statement
Followed up by the following (possibly more current) registration
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
NTR-new | NL6157 |
NTR-old | NTR6304 |
CCMO | NL56007.091.15 |
OMON | NL-OMON43451 |